1. Pharmaco-genomic mutation labeling process comprising steps: testing a pharmaco-genomic mutation in order to electronically label such mutation using a semiconductor nanocrystal or quantum-dot probe device that provides detectable label that links or bonds to one or more affinity molecules of a detectable substance in an analyte associated with the pharmaco-genomic mutation, whereupon such nanocrystal or quantum-dot probe device responds to a first energy associated with presence of a detectable pharmaco-genomic mutation substance within a material bonded to such probe device, and thereby exciting the nanocrystal or quantum-dot in the probe device to cause such probe device to provide a second energy that fluoresces a distinct wavelength signal that indicates presence of the pharmaco-genomic mutation, wherein said semiconductor nanocrystal or quantum-dot probe device couples to an affinity-based bio sensor comprising an optical evanescent wave detector using flow-based surface plasmon resonance provided in micro-fabricated integrated fluidic cartridge to capture tagged proteins, thiol coupling or coil-coil interaction for testing the pharmaco-genomic mutation, wherein resonance angle is continuously monitored to detect changes in refractive resonance angle and refractive index corresponding to changes in mass when one or more ligand binds to or dissociates from immobilized binding partner associated with the tested pharmaco-genomic mutation, such that both the semiconductor nanocrystal or quantum-dot probe device and the affinity-based biosensor detect the same pharmaco-genomic mutation, said detected same pharmaco-genomic mutation thereby indicating patient ability to produce thiopurine S-methyltransferase (TPMT) enzyme activity being compromised effectively by identifying patient being at risk for 6-MP/azathioprine/thioguanine toxicity, and said same pharmaco-genomic mutation further enabling detection of G protein-coupled receptors (GPCR) molecular target and variant alleles, as well as enzyme debrisoquine hydroxylase (CYP2D6) associated with isozyme of microsomal cytochrome P450 monooxygenase system, whereby encoding gene is located in CYP2D gene cluster in contiguous 45-kb region of chromosome 22; and comparing by a processor coupled to the probe device the tested pharmaco-genomic mutation with other pharmaco-genomic mutations to enable automated analysis of the tested pharmaco-genomic-mutation, wherein the processor is embodied in a hand-held mobile personal digital assistant device capable of electronic storage, display, and access to sensor elements comprising the semiconductor nanocrystal or quantum-dot probe device and the affinity-based bio sensor, such that the processor is enabled to compare the tested pharmaco-genomic mutation with one or more other pharmaco-genomic mutation by accessing the tested pharmaco-genomic mutation via the semiconductor nanocrystal or quantum-dot probe device, and said other pharmaco-genomic mutation via the affinity-based biosensor, whereby automated analysis by the processor of the tested pharmaco-genomic mutation and said other pharmaco-genomic mutation is automatically enabled by the processor using a virtual cell system that automates design synthesis, test, and simulation of the tested pharmaco-genomic mutation and said other pharmaco-genomic mutation, thereby enabling comparative perturbation or mutagenesis stimulation of pharmaco-genomic mutations sensed separately by the semiconductor nanocrystal or quantum-probe device and the affinity-based bio sensor.